急性并发症高发：52.7%的中国患儿诊断时合并糖尿病酮症酸中毒（DKA），5岁以下儿童比例更高达56.9%。DKA不仅增加死亡风险，还与远期血糖控制不良、神经认知缺陷密切相关。

A record entirely from the South, in a sector that has always been a thorn in the side. At the University Hospital of Palermo ...

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease ...

Provention is seeking approval of teplizumab as a treatment to delay clinical type 1 diabetes in at-risk individuals, hoping the drug can become the first disease-modifying therapy in these patients.

Teplizumab is an immunotherapy drug designed to delay the onset of Type 1 diabetes (T1D) in those who have a confirmed diagnosis of T1D without clinical symptoms, as determined through the assessment ...